Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F H Messerli

Showing results (311-320 of 338) with videos related to

Pageof 34
Sort By:
Angiology|September 1, 1975
Labile (borderline) hypertension--new aspects of a common disorderO Kuchel, J L Cuche, P Hamet, et al.
Archives of Internal Medicine|June 1, 1989
Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmiasF H Messerli, B D Nunez, M M Nunez, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1981
Antiadrenergic therapy: special aspects in hypertension in the elderlyF H Messerli, G R Dreslinski, F E Husserl, et al.
Contributions to Nephrology|January 1, 1982
Obesity and essential hypertensionF H Messerli, H O Ventura, E D Reisin, et al.
Circulation Research|June 1, 1976
Plasma cyclic adenosine 3':5'-monophosphate response to isoproterenol and glucagon in hyperkinetic borderline (labile) hypertensionF H Messerli, O Kuchel, P Hamet, et al.
Journal of the American College of Cardiology|May 1, 1983
Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexesF G Dunn, W Oigman, K Sungaard-Riise, et al.
Canadian Medical Association Journal|May 7, 1977
Renal vein plasma adenosine 3',5'-cyclic monophosphate in renovascular hypertensionO Kuchel, F H Messerli, G Tolis, et al.
Circulation|March 1, 1976
Mineralocorticoid secretion in essential hypertension with normal and low plasma renin activityF H Messerli, O Kuchel, W Nowaczynski, et al.
Circulation|June 1, 1984
Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertensionH O Ventura, F H Messerli, E D Frohlich, et al.
JAMA|October 21, 1988
The TPA controversy and the drug approval process. The view of the Cardiovascular and Renal Drugs Advisory CommitteeP R Kowey, L Fisher, E G Giardina, et al.
Pageof 34

Showing results (311-320 of 338) with videos related to

Sort By:
Pageof 34
Angiology|September 1, 1975
Labile (borderline) hypertension--new aspects of a common disorderO Kuchel, J L Cuche, P Hamet, et al.
Archives of Internal Medicine|June 1, 1989
Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmiasF H Messerli, B D Nunez, M M Nunez, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1981
Antiadrenergic therapy: special aspects in hypertension in the elderlyF H Messerli, G R Dreslinski, F E Husserl, et al.
Contributions to Nephrology|January 1, 1982
Obesity and essential hypertensionF H Messerli, H O Ventura, E D Reisin, et al.
Circulation Research|June 1, 1976
Plasma cyclic adenosine 3':5'-monophosphate response to isoproterenol and glucagon in hyperkinetic borderline (labile) hypertensionF H Messerli, O Kuchel, P Hamet, et al.
Journal of the American College of Cardiology|May 1, 1983
Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexesF G Dunn, W Oigman, K Sungaard-Riise, et al.
Canadian Medical Association Journal|May 7, 1977
Renal vein plasma adenosine 3',5'-cyclic monophosphate in renovascular hypertensionO Kuchel, F H Messerli, G Tolis, et al.
Circulation|March 1, 1976
Mineralocorticoid secretion in essential hypertension with normal and low plasma renin activityF H Messerli, O Kuchel, W Nowaczynski, et al.
Circulation|June 1, 1984
Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertensionH O Ventura, F H Messerli, E D Frohlich, et al.
JAMA|October 21, 1988
The TPA controversy and the drug approval process. The view of the Cardiovascular and Renal Drugs Advisory CommitteeP R Kowey, L Fisher, E G Giardina, et al.
Pageof 34